Maggie Scully, Ph.D., is Director of the Partnership Development Office at the Frederick National Laboratory. Prior to joining the Partnership Development Office, Scully was a scientist at the Nanotechnology Characterization Lab at the Frederick National Laboratory. She spent over nine years at the laboratory bench engineering and validating nanoparticles for drug delivery and imaging applications, predominantly for cancer indications.
Scully co-founded a start-up company dedicated to the clinical translation of biopharmaceuticals for cancer, diabetes, and rare disease indications. The company is based on licensed technology from Johns Hopkins University and currently part of a large clinical-stage parent company.
Scully was a postdoctoral fellow at Johns Hopkins Institute for NanoBioTechnology and Johns Hopkins School of Medicine’s Department of Radiology. As a doctoral student, Scully was in the NIH Intramural Research Program at the National Institute of Biomedical Imaging and Bioengineering. She received her Ph.D. in Biomedical Engineering from Stony Brook University and her B.S. in Bioengineering from Lehigh University.
